TN2009000275A1 - Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome - Google Patents

Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome

Info

Publication number: TN2009000275A1
Authority: TN; Tunisia
Prior art keywords: treatment; metabolic syndrome; acid derivatives; substituted pyranone; substituted
Prior art date: 2007-01-16

Application number

TNP2009000275A

Other languages

English (en)

Inventor

Harm Brummerhop

Siegfried Stengelin

Hubert Heuer

Susanne Kilp

Andreas Herling

Thomas Klabunde

Dieter Kadereit

Matthias Urmann

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-01-16

Filing date

2009-06-26

Publication date

2010-10-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39232744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000275(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-06-26 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

2010-10-18 Publication of TN2009000275A1 publication Critical patent/TN2009000275A1/fr

Links

208000001145 Metabolic Syndrome Diseases 0.000 title abstract 3
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title abstract 3
ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical class O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 title abstract 2
VOLMSPGWNYJHQQ-UHFFFAOYSA-N Pyranone Natural products CC1=C(O)C(=O)C(O)CO1 VOLMSPGWNYJHQQ-UHFFFAOYSA-N 0.000 title abstract 2
239000002253 acid Substances 0.000 title abstract 2
239000003814 drug Substances 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Neurology (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Child & Adolescent Psychology (AREA)
Immunology (AREA)
Psychology (AREA)
Psychiatry (AREA)
Virology (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)

TNP2009000275A 2007-01-16 2009-06-26 Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome TN2009000275A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102007002260A DE102007002260A1 (de)	2007-01-16	2007-01-16	Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
PCT/EP2008/000029 WO2008086949A1 (fr)	2007-01-16	2008-01-04	Utilisation de dérivés acides de pyranone substitués dans le traitement du syndrome métabolique

Publications (1)

Publication Number	Publication Date
TN2009000275A1 true TN2009000275A1 (en)	2010-10-18

Family

ID=39232744

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000275A TN2009000275A1 (en)	2007-01-16	2009-06-26	Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome

Country Status (31)

Country	Link
US (1)	US8748483B2 (fr)
EP (1)	EP2120923B1 (fr)
JP (1)	JP2010515765A (fr)
KR (1)	KR20090110834A (fr)
CN (1)	CN101600427A (fr)
AR (1)	AR064899A1 (fr)
AU (1)	AU2008207170A1 (fr)
BR (1)	BRPI0806661A2 (fr)
CA (1)	CA2675442A1 (fr)
CL (1)	CL2008000110A1 (fr)
CR (1)	CR10850A (fr)
CY (1)	CY1113148T1 (fr)
DE (1)	DE102007002260A1 (fr)
DK (1)	DK2120923T3 (fr)
DO (1)	DOP2009000177A (fr)
EC (1)	ECSP099518A (fr)
ES (1)	ES2390513T3 (fr)
HR (1)	HRP20120763T1 (fr)
IL (1)	IL199829A0 (fr)
MA (1)	MA31094B1 (fr)
MX (1)	MX2009006913A (fr)
PE (1)	PE20081700A1 (fr)
PL (1)	PL2120923T3 (fr)
PT (1)	PT2120923E (fr)
RS (1)	RS52494B (fr)
RU (1)	RU2009131058A (fr)
SI (1)	SI2120923T1 (fr)
TN (1)	TN2009000275A1 (fr)
TW (1)	TW200836716A (fr)
UY (1)	UY30871A1 (fr)
WO (1)	WO2008086949A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2011107494A1 (fr)	2010-03-03	2011-09-09	Sanofi	Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
WO2011157827A1 (fr)	2010-06-18	2011-12-22	Sanofi	Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (fr)	2011-09-12	2013-03-21	Sanofi	Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr)	2011-09-27	2015-10-21	Sanofi	Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
WO2014090363A1 (fr) *	2012-12-13	2014-06-19	Merck Patent Gmbh	Dérivés de 3-hydroxy-4-oxo-4h-pyrane ou de 3-hydroxy-4-oxo-1,4-dihydropyridine utilisés comme substances actives adhérant aux protéines
JP6338276B2 (ja) *	2014-07-10	2018-06-06	学校法人神奈川大学	抗癌剤
BR112023002497A2 (pt) *	2020-08-12	2023-05-02	Spruce Biosciences Inc	Métodos e composições para tratamento da síndrome dos ovários policísticos

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3152148A (en)	1963-01-03	1964-10-06	Dow Chemical Co	Preparation of comenic and pyromeconic acids
DE2966702D1 (en)	1978-06-26	1984-03-29	Measurex Corp	Method and apparatus for measuring gas, including standardisation
JPS59125644A (ja)	1982-12-29	1984-07-20	Fujitsu Ltd	半導体装置
US4603144A (en)	1984-08-16	1986-07-29	G. D. Searle & Co.	Kojic acid ether-ester derivatives
GB8615041D0 (en) *	1986-06-20	1986-07-23	Silver J	Pharmaceutical compositions
DE3728602A1 (de)	1987-08-27	1989-03-09	Bayer Ag	Faserverstaerktes polyphenylensulfid
DE3728924A1 (de)	1987-08-29	1989-03-09	Bayer Ag	Flammwidrige, thermoplastische formmassen auf basis von polycarbonat, polyalkylenterephthalat, pfropfcopolymerisat, fluoriertem polyolefin und phosphorverbindung
DE3729586A1 (de)	1987-09-04	1989-03-16	Ant Nachrichtentech	Verfahren zum ausgleichen von durch den doppler-effekt hervorgerufenen laufzeit-verschiebungen der bursts in einem tdma-rahmen sowie anordnung
CA2007414C (fr)	1989-04-26	1994-10-25	Clayton James Bennett Iii	Methode de manipulation d'elements presents dans un document structure a l'aide d'interpretations actives
FR2663336B1 (fr)	1990-06-18	1992-09-04	Adir	Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH06271500A (ja) *	1993-03-23	1994-09-27	Noguchi Kenkyusho	コマン酸の製造法
DE19530298C2 (de) *	1995-08-17	1999-07-22	Woerwag Pharma Gmbh	Verwendung von Orotsäure zur Prävention und Therapie des metabolischen Syndroms
AU727775B2 (en)	1996-01-17	2000-12-21	Novo Nordisk A/S	Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
UA51716C2 (uk)	1996-07-08	2002-12-16	Авентіс Фармасьютікалз Продактс Інк.	Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
DE69737479D1 (de)	1996-08-30	2007-04-26	Novo Nordisk As	Glp-1 derivate
HUP0301101A3 (en)	1996-12-31	2009-03-30	Reddy S Res Foundation	Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
DE19726167B4 (de)	1997-06-20	2008-01-24	Sanofi-Aventis Deutschland Gmbh	Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
PL338013A1 (en)	1997-07-16	2000-09-25	Novo Nordisk As	Derivatives of condensed 1,2,4-thiadiazine, their production and application
CO4970713A1 (es)	1997-09-19	2000-11-07	Sanofi Synthelabo	Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
US6221897B1 (en)	1998-06-10	2001-04-24	Aventis Pharma Deutschland Gmbh	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de)	1998-10-02	2000-07-13	Aventis Pharma Gmbh	Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en)	1999-01-08	1999-02-24	Alizyme Therapeutics Ltd	Inhibitors
JP2002542245A (ja)	1999-04-16	2002-12-10	ノボノルディスクアクティーゼルスカブ	置換イミダゾール、それらの製造および使用
CN1331862C (zh)	1999-04-28	2007-08-15	萨诺费－阿文蒂斯德国有限公司	作为ppar受体配体的二芳基酸衍生物
BR0010126A (pt)	1999-04-28	2002-02-26	Aventis Pharma Gmbh	Derivados de ácido tri-arìlico como ligandos receptores de ppar
AU4808300A (en)	1999-04-30	2000-11-17	Neurogen Corporation	9h-pyrimido(4,5-b)indole derivatives: crf1 specific ligands
GB9911863D0 (en)	1999-05-21	1999-07-21	Knoll Ag	Therapeutic agents
DE60029446T2 (de)	1999-06-18	2007-02-08	Merck & Co., Inc.	Arylthiazolidindione und aryloxazolidindion-derivate
DE60004066T2 (de)	1999-07-29	2004-04-15	Eli Lilly And Co., Indianapolis	Benzofurylpiperazine: 5-ht2c serotoninrezeptor agonisten
PT1218341E (pt)	1999-09-01	2005-11-30	Sanofi Aventis Deutschland	Derivados de sulfonilcarboxamidas, processo para a sua preparacao e sua utilizacao como medicamentos
KR100502876B1 (ko)	2000-04-28	2005-07-21	아사히 가세이 파마 가부시키가이샤	신규 이환성 화합물
BR0110638A (pt)	2000-05-11	2003-03-25	Bristol Myers Squibb Co	Análogos de tetraidroisoquinolina úteis como secretagogos de hormÈnio do crescimento
WO2001091752A1 (fr)	2000-05-30	2001-12-06	Merck & Co., Inc.	Agonistes du recepteur de la melanocortine
DE10033353A1 (de)	2000-07-08	2002-01-24	Aventis Pharma Gmbh	Breit einsetzbares Verfahren zur Identifizierung von Modulatoren von G-Protein gekoppelten Rezeptoren
FR2814678B1 (fr)	2000-10-04	2002-12-20	Aventis Pharma Sa	Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
IL156552A0 (en)	2000-12-21	2004-01-04	Aventis Pharma Gmbh	Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
RU2330846C2 (ru)	2001-08-31	2008-08-10	Санофи-Авентис Дойчланд Гмбх	Диарилциклоалкильные производные, способ их получения и их применение в качестве ppar-активаторов
US6552073B1 (en)	2002-03-01	2003-04-22	Exonhit Therapeutics Sa	Compounds and methods of treating cell proliferative diseases
DE10227506A1 (de)	2002-06-19	2004-01-08	Aventis Pharma Deutschland Gmbh	Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227507A1 (de)	2002-06-19	2004-01-08	Aventis Pharma Deutschland Gmbh	Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227508A1 (de)	2002-06-19	2004-01-08	Aventis Pharma Deutschland Gmbh	Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10307004B3 (de)	2003-02-19	2004-08-05	Siemens Ag	Verfahren zur Steuerung einer Brennkraftmaschine mit einer Lambda-Regelung

2007
- 2007-01-16 DE DE102007002260A patent/DE102007002260A1/de not_active Withdrawn
2008
- 2008-01-04 KR KR1020097014783A patent/KR20090110834A/ko not_active Withdrawn
- 2008-01-04 JP JP2009545849A patent/JP2010515765A/ja not_active Withdrawn
- 2008-01-04 PL PL08700981T patent/PL2120923T3/pl unknown
- 2008-01-04 MX MX2009006913A patent/MX2009006913A/es not_active Application Discontinuation
- 2008-01-04 SI SI200830757T patent/SI2120923T1/sl unknown
- 2008-01-04 DK DK08700981.7T patent/DK2120923T3/da active
- 2008-01-04 CA CA002675442A patent/CA2675442A1/fr not_active Abandoned
- 2008-01-04 RU RU2009131058/15A patent/RU2009131058A/ru unknown
- 2008-01-04 RS RS20120437A patent/RS52494B/en unknown
- 2008-01-04 PT PT08700981T patent/PT2120923E/pt unknown
- 2008-01-04 BR BRPI0806661-2A patent/BRPI0806661A2/pt not_active IP Right Cessation
- 2008-01-04 EP EP08700981A patent/EP2120923B1/fr active Active
- 2008-01-04 ES ES08700981T patent/ES2390513T3/es active Active
- 2008-01-04 CN CNA2008800023932A patent/CN101600427A/zh active Pending
- 2008-01-04 WO PCT/EP2008/000029 patent/WO2008086949A1/fr active Application Filing
- 2008-01-04 AU AU2008207170A patent/AU2008207170A1/en not_active Abandoned
- 2008-01-14 AR ARP080100165A patent/AR064899A1/es not_active Application Discontinuation
- 2008-01-14 TW TW097101284A patent/TW200836716A/zh unknown
- 2008-01-14 PE PE2008000138A patent/PE20081700A1/es not_active Application Discontinuation
- 2008-01-14 UY UY30871A patent/UY30871A1/es not_active Application Discontinuation
- 2008-01-15 CL CL200800110A patent/CL2008000110A1/es unknown
2009
- 2009-06-09 CR CR10850A patent/CR10850A/es not_active Application Discontinuation
- 2009-06-26 TN TNP2009000275A patent/TN2009000275A1/fr unknown
- 2009-07-13 DO DO2009000177A patent/DOP2009000177A/es unknown
- 2009-07-13 IL IL199829A patent/IL199829A0/en unknown
- 2009-07-14 MA MA32090A patent/MA31094B1/fr unknown
- 2009-07-15 EC EC2009009518A patent/ECSP099518A/es unknown
- 2009-07-16 US US12/504,198 patent/US8748483B2/en not_active Expired - Fee Related
2012
- 2012-09-26 HR HRP20120763AT patent/HRP20120763T1/hr unknown
- 2012-09-27 CY CY20121100882T patent/CY1113148T1/el unknown

Also Published As

Publication number	Publication date
PT2120923E (pt)	2012-08-31
PE20081700A1 (es)	2009-01-08
EP2120923B1 (fr)	2012-07-18
CR10850A (es)	2009-10-16
US20100144862A1 (en)	2010-06-10
MA31094B1 (fr)	2010-01-04
SI2120923T1 (sl)	2012-10-30
AR064899A1 (es)	2009-05-06
DE102007002260A1 (de)	2008-07-31
DK2120923T3 (da)	2012-10-29
HRP20120763T1 (hr)	2012-10-31
JP2010515765A (ja)	2010-05-13
UY30871A1 (es)	2008-09-02
WO2008086949A1 (fr)	2008-07-24
US8748483B2 (en)	2014-06-10
ECSP099518A (es)	2009-08-28
CY1113148T1 (el)	2016-04-13
IL199829A0 (en)	2010-04-15
PL2120923T3 (pl)	2012-12-31
RS52494B (en)	2013-02-28
AU2008207170A1 (en)	2008-07-24
BRPI0806661A2 (pt)	2011-09-06
EP2120923A1 (fr)	2009-11-25
RU2009131058A (ru)	2011-02-27
MX2009006913A (es)	2009-08-12
CL2008000110A1 (es)	2008-05-16
CN101600427A (zh)	2009-12-09
DOP2009000177A (es)	2009-08-15
KR20090110834A (ko)	2009-10-22
TW200836716A (en)	2008-09-16
ES2390513T3 (es)	2012-11-13
CA2675442A1 (fr)	2008-07-24

Publication	Publication Date	Title
TN2009000275A1 (en)	2010-10-18	Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
MX2014000341A (es)	2014-05-01	Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
EA201491060A1 (ru)	2014-09-30	Новые производные трифторметилоксадиазола и их применение для лечения заболевания
HK1149258A1 (en)	2011-09-30	Compounds
PH12013500473A1 (en)	2013-05-06	Triazine-oxadiazoles
MX2014004479A (es)	2014-08-01	Derivados de oxazina novedosos y su uso en el tratamiento de enfermedades.
NZ601483A (en)	2013-10-25	Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
SG155961A1 (en)	2009-10-29	Pyrazoles as 11-beta-hsd-1
MX2010013682A (es)	2011-03-15	Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
IN2012DN03182A (fr)	2015-09-25
GB0722077D0 (en)	2007-12-19	Compounds
SI2150530T1 (sl)	2012-02-29	Substituirani sulfonamidni derivati
PH12013500007A1 (en)	2017-05-19	Piperidine derivatives and their use for the treatment of metabolic disorders
CR20200286A (es)	2020-09-23	DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
MX2011011733A (es)	2012-02-01	Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos.
MX2009013501A (es)	2010-01-18	Compuestos piperidinicos y sus usos.
MX2012008328A (es)	2012-08-08	Derivados de pirazina.
WO2012135615A3 (fr)	2013-01-03	Enopeptines, utilisations de celles-ci, et procédés de synthèse de celles-ci
MX2009010374A (es)	2010-03-04	Derivados de tetrahidro-naftalenamina sustituidos con heterociclilo, su preparacion y su uso como medicamentos.
PH12015500111A1 (en)	2015-03-30	Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
WO2009003719A3 (fr)	2009-08-13	Dérivés d'indane-amine, leur préparation et leur utilisation comme médicaments
WO2010121675A3 (fr)	2011-02-24	Thiazolyl-benzimidazoles
TN2010000266A1 (en)	2011-11-11	Oxazolidinones for the treatment and/or prophylaxis of heart failure
MX2009005912A (es)	2009-07-22	Derivados de etilamina-fenilo heterociclilo sustituidos, su preparacion y uso como medicamentos.
WO2006099942A3 (fr)	2007-06-21	Utilisation de 8-n-benzimidazoles a substitution amino